Remove Manufacturing Remove Personality disorders Remove Pharmaceuticals
article thumbnail

NRx Pharmaceuticals Applies for FDA National Priority Voucher for Intravenous Ketamine (NRX-100)

Psychiatric Times

SHOW MORE NRx Pharmaceuticals advances NRX-100, a preservative-free ketamine, through a fast-tracked FDA review for treating suicidal depression and PTSD. Sanom/Adobestock BREAKING NEWS A new formulation of ketamine is progressing through a novel US Food and Drug Administration review pathway, announced NRx Pharmaceuticals.

article thumbnail

June in Review: Updates on the Psychiatric Treatment Pipeline

Psychiatric Times

NRx Pharmaceuticals seeks FDA approval for NRX-100, a preservative-free ketamine for suicidal depression and PTSD, via the National Priority Voucher pathway. A recently filed patent on its preservative-free manufacturing process may further support market exclusivity.